Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine cerebroside + porcine ganglioside is a neurotrophic combination therapy derived from porcine brain tissue, primarily used in China for the treatment of central nervous system disorders such as ischemic stroke and cerebral infarction. The drug consists of gangliosides, which are essential for neuronal membrane stability and signal transduction, and cerebrosides, which are critical components of the myelin sheath. Together, these components work synergistically to provide neuroprotection, reduce excitotoxicity, and promote the repair and regeneration of damaged neural tissue. It is typically administered via intravenous injection and has been studied in Phase 4 clinical trials by institutions like the Affiliated Hospital of Zunyi Medical University to confirm its efficacy in improving neurological outcomes following acute brain injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on porcine cerebroside + porcine ganglioside.